ArticleInfection prevention in practice2025
Prevalence of difficult-to-treat resistance in ESKAPE pathogens in a third level hospital in Mexico.
Article in Infection prevention in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Prevalence and antimicrobial resistance trends of ESKAPEE pathogens in clinical isolates from Hyderabad, Pakistan: a cross-sectional study.IJID regions · 2026Article
- A multipurpose 1DZnO nanoplatform to combat ampicillin-resistant E. coli.Scientific reports · 2026Article
- Clinical risk factors for multidrug-resistant organism infections in postoperative gastric cancer patients: an ICU-based retrospective analysis.BMC infectious diseases · 2026Article
- Genetic Analysis of Virulence and β-Lactamase Determinants Related to β-Lactamase Inhibitors inAntibiotics (Basel, Switzerland) · 2025Article
- City or Suburb, Resistance Flows: Wastewater-BorneAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antimicrobial resistance and difficult-to-treat resistance (DTR) in ESKAPE pathogens ( Methods: Antimicrobial susceptibility testing was determined by either disk diffusion or broth microdilution in strains from 2018 to 2023. Isolates were screened for carbapenemase genes. Multidrug resistance (MDR), extensively drug resistance (XDR), carbapenem resistance (CR), extended-spectrum cephalosporin-resistance (ESCR), fluoroquinolone resistance (FQR), and DTR were determined. Results: From 3,239 strains, 48.5% were from respiratory infections, resistance was 87.5% to meticillin in Conclusions: Antimicrobial resistance rates were high in Gram-negative pathogens. CR and DTR rates were higher in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.